不同LDL-C水平冠心病PCI术后患者的SYNTAX、SYNTAX Ⅱ评分变化

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (427 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the changes of SYNTAX and SYNTAX Ⅱ scores in patients with coronary artery heart disease (CHD) after percutaneous coronary intervention (PCI) with different low-density lipoprotein cholesterol (LDL-C) level. Methods A total of 150 patients who underwent PCI for CHD in Wujin Hospital Affiliated to Jiangsu University from October 2017 to December 2019 were selected as the research objects. LDL-C level was detected after PCI, and SYNTAX and SYNTAX Ⅱ scores were calculated, and clinical data of patients were collected. According to their LDL-C levels, all research objects were divided into low LDL-C level group (LDL-C＜1.4 mmol/L, 23 cases), non-low LDL-C level group (1.4≤LDL-C ＜1.8 mmol/L, 54 cases) and substandard LDL-C group (LDL-C≥1.8 mmol/L, 73 cases). The changes of SYNTAX and SYNTAX Ⅱ scores in the three groups after PCI were compared. Results There was no significant difference in clinical data among the three groups (all P ＞ 0.05). There were statistically significant differences in SYNTAX and SYNTAX Ⅱ scores among the three groups after PCI (P ＜ 0.05). Further pair comparison showed that SYNTAX and SYNTAX Ⅱ scores of the non-low LDL-C level group and the substandard LDL-C group were higher than those of the low LDL-C level group. The scores of SYNTAX and SYNTAX Ⅱ in the substandard LDL-C group were higher than those in the non-low LDL-C level group, and the differences were statistically significant (all P ＜ 0.05). Conclusion Low LDL-C level can further delay the progression of coronary artery in patients with CHD after PCI.

Key words： Coronary artery heart disease Low-density lipoprotein cholesterol SYNTAX score SYNTAX Ⅱ score

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Kerui1 LI Yong2

Cite this article:

ZHANG Kerui1 LI Yong2. Changes of SYNTAX and SYNTAX Ⅱ scores in patients with coronary artery heart disease after PCI with different LDL-C level[J]. 中国医药导报, 2021, 18(17): 68-72.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I17/68

[1] Stone NJ，Robinson JG，Lichtenstein AH，et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol，2014，63：2889-2934.
[2] Baigent C，Keech A，Kearney PM，et al. Efficacy and safety of cholesterol-lowering treatment：prospective meta-analysis of data from 90，056 participants in 14 randomised trials of statins [J]. Lancet，2005，366：1267-1278.
[3] Mach F，Baigent C，Catapano AL，et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias：lipid modification to reduce cardiovascular risk [J]. Eur Heart J，2020，411（1）：140-205.
[4] Cannon CP，Braunwald E，Mccabe CH，et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes [J]. N Engl J Med，2004，350：1495-1502.
[5] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志，2016，31（10）：937-953.
[6] 中国胆固醇教育计划（CCEP）工作委员会，中国医疗保健国际交流促进会动脉粥样硬化血栓疾病防治分会，中国老年学和老年医学学会心血管病分会，等.中国胆固醇教育计划调脂治疗降低心血管事件专家建议（2019）[J].中华内科杂志，2020，59（1）：18-22.
[7] Levine GN，Bates ER，Blankenship JC，et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention： a report of the American college of cardiology foundation /American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions [J]. Circulation，2011，124（23）：e574-e651．
[8] Farooq U，Van KD，Steyerberg EW，et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients：development and validation of SYNTAX score Ⅱ [J]. Lancet，2013，381（9867）：639-650.
[9] 姚艳妮，胡越成，丛洪良，等.SYNTAX评分及其衍生评分的研究进展[J].中华心血管病杂志，2017，45（4）：341-344.
[10] Wijns W，Kolh P，Danchin N，et al. Guidelines on myocardial revascularization [J]. Eur Heart J，2010，31（20）：2501-2555．
[11] Ference BA，Ginsberg HN，Graham I，et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic，epidemiologic，and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J]. Eur Heart J，2017，38 （32）：2459-2472.
[12] Okuyama H，Hamazaki T，Hama R，et al. Acritical review of the consensuss tatement from the European Atherosclerosis Society Consensus Panel 2017 [J]. Pharmacology，2018，101（3/4）：184-218.
[13] Thomas F. “The lower the better”revisited：the new lipid targets in high risk patients [J]. Eur Heart J，2020，41（1）：1-3.
[14] Ference BA，Robinson JG，Brook RD，et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes [J]. N Engl Med，2016，375：2144-2153.
[15] Sattar N，Preiss D，Murray HM，et al. Statins and risk of incident diabetes：a collaborative meta-analysis of randomised statin trials [J]. Lancet，2010，375（9716）：735-742.
[16] Rist PM，Buring JE，Ridker PM，et al. Lipid levels and the risk of hemorrhagic stroke among women [J]. Neurology，2019，92（19）：e2286-e2294.
[17] Ma C，Gurol ME，Huang Z，et al. Low-density lipoprotein cholesterol and risk of intra-cerebral hemorrhage [J]. Neurology，2019，93（19）：e1-e13.
[18] Jacobs D，Blackburn H，Higgins M，et al. Report of the conference on low blood cholesterol：mortality associations [J]. Circulation，1992，86（3）：1046-1060.
[19] Alsheikh-Ali AA，Maddukuri PV，Han H，et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes，rhabdomyolysis，and cancer： insights from large randomized statin trials [J]. J Am Coll Cardiol，2007，50（5）：409-418.
[20] Giugliano RP，Cannon CP，Blazing MA，et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus：Results From IMPROVE-IT（Improved Reduction of Outcomes：Vytorin Efficacy International Trial） [J]. Circulation，2018，137：1571-1582.
[21] Goodman SG，Steg PG，Szarek M，et al. Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES [J]. J Am Coll Cardiol，2020， 75：448-451.
[22] HPS2-THRIVE Collaborative Group，Landray MJ，Haynes R，et al. Effects of extended -release niacin with laropiprant in high-risk patients [J]. N Engl J Med，2014，371：203-212.
[23] Ryan A，Heath S，Cook P. Dyslipidaemia and cardiovascular risk [J]. BMJ，2018，360：k835.